McMaster University

Medical Sciences
Graduate Program

Scope of Search


Laurie C. Doering

Laurie C. Doering


BSc, MSc, PhD
Professor Emeritus

Research Interests

The laboratory studies the cell biology of neural stem cells in normal development and in neurodevelopmental disorders with a current focus on autism and Fragile X syndrome (FXS). Our research uses a knockout mouse model of Fragile X syndrome to study the effect of the affected gene on stem cell lineage biology. A variety of methods are used to evaluate how astrocytes can correct the neuronal phenotype in autism.

Tissue culture, neural stem cells, Fragile X knockout mouse, astrocytes, immunocytochemistry, confocal microscopy and imaging.



Academic Interests

Dr. Doering is very involved in teaching within the Faculty of Health Sciences.

Academic involvement

Graduate Studies

Medical Sciences Program

  • Biochemistry and Biomedical Sciences Program
  • Radiology and Surgery Residency Training

Undergraduate Studies

  • Education Program in Anatomy
  • Undergraduate Medical Program —
    Medical Foundations 1, 2, 3 and 5



McMaster University
Health Sciences Centre

telephone: (905) 525-9140 ext. 22913


Program Area

Physiology & Pharmacology


Research Focus

Tissue culture, transplantation of stem cells into the CNS, immunocytochemistry, fluorescence and confocal microscopy

Selected Publications

  • Pacey LKK and Doering LC (2012). Expression of FMRP by neurosphere derived cells following transplantation in the Fragile X mouse model. J Stem Cell Res Ther S12:001. doi:10.4172/2157-7633.S12-001
  • Cheng C, Sourial M and Doering LC (2012) Astrocytes and developmental plasticity in Fragile X. Neural Plasticity Volume 2012 (2012), Article ID 197491, 12 pages, doi:10.1155/2012/197491.
  • Wang H and Doering LC (2012) Induced pluripotent stem cells to model and treat neurogenetic disorders (Review). Neural Plasticity Volume 2012 (2012), Article ID 346053, 15 pages doi:10.1155/2012/ 346053.
  • Wang H and Doering LC (2013) Reversing autism by targeting downstream mTOR signaling. Frontiers Cellular Neuroscience 7:28. doi: 10.3389/ fncel.2013.00028
  • Sourial M, Cheng C and Doering LC (2013) Progress toward therapeutic potential for AFQ056 in Fragile X syndrome. Journal of Experimental Pharmacology 5:45 – 54 DOI: